Open this publication in new window or tab >>Show others...
2018 (English)In: Theranostics, ISSN 1838-7640, E-ISSN 1838-7640, Vol. 8, no 17, p. 4710-4732Article in journal (Refereed) Published
Abstract [en]
Cardiovascular diseases are the leading cause of death worldwide. Despite preventive efforts, early detection of atherosclerosis, the common pathophysiological mechanism underlying cardiovascular diseases remains elusive, and overt coronary artery disease or myocardial infarction is often the first clinical manifestation. Nanoparticles represent a novel strategy for prevention, diagnosis, and treatment of atherosclerosis, and new multifunctional nanoparticles with combined diagnostic and therapeutic capacities hold the promise for theranostic approaches to this disease. This review focuses on the development of nanosystems for therapy and diagnosis of subclinical atherosclerosis, coronary artery disease, and myocardial infarction and the evolution of nanosystems as theranostic tools. We also discuss the use of nanoparticles in noninvasive imaging, targeted drug delivery, photothermal therapies together with the challenges faced by nanosystems during clinical translation.
Place, publisher, year, edition, pages
Ivyspring International Publisher, 2018
Keywords
Nanoparticles, theranostics, atherosclerosis, myocardial infarction, cardiovascular diseases
National Category
Other Health Sciences
Research subject
Health Science
Identifiers
urn:nbn:se:ltu:diva-71027 (URN)10.7150/thno.26284 (DOI)000444107300011 ()30279733 (PubMedID)2-s2.0-85053130172 (Scopus ID)
Note
Validerad;2018;Nivå 2;2018-09-28 (svasva)
2018-09-282018-09-282023-05-06Bibliographically approved